Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;9(3):1269-1277.
doi: 10.1007/s13300-018-0436-y. Epub 2018 May 9.

Artificial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Xia Dai  1 , Zu-Chun Luo  2 , Lu Zhai  1 , Wen-Piao Zhao  1 , Feng Huang  3
Affiliations

Artificial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Xia Dai et al. Diabetes Ther. 2018 Jun.

Abstract

Introduction: Insulin injection is the main treatment in patients with type 1 diabetes mellitus (T1DM). Even though continuous glucose monitoring has significantly improved the conditions of these patients, limitations still exist. To further enhance glucose control in patients with T1DM, an artificial pancreas has been developed. We aimed to systematically compare artificial pancreas with its control group during a 24-h basis in patients with T1DM.

Methods: Electronic databases were carefully searched for English publications comparing artificial pancreas with its control group. Overall daytime and nighttime glucose parameters were considered as the endpoints. Data were evaluated by means of weighted mean differences (WMDs) and 95% confidence intervals (CIs) generated by RevMan 5.3 software.

Results: A total number of 354 patients were included. Artificial pancreas significantly maintained a better mean concentration of glucose (WMD - 1.03, 95% CI - 1.32 to - 0.75; P = 0.00001). Time spent in the hypoglycemic phase was also significantly lower (WMD - 1.23, 95% CI - 1.56 to - 0.91; P = 0.00001). Daily insulin requirement also significantly favored artificial pancreas (WMD - 3.43, 95% CI - 4.27 to - 2.59; P = 0.00001). Time spent outside the euglycemic phase and hyperglycemia phase (glucose > 10.0 mmol/L) also significantly favored artificial pancreas. Also, the numbers of hypoglycemic events were not significantly different.

Conclusion: Artificial pancreas might be considered an effective and safe alternative to be used during a 24-h basis in patients with T1DM.

Keywords: Artificial pancreas; Glucose control; Type 1 diabetes mellitus.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram representing the study selection
Fig. 2
Fig. 2
Comparing artificial pancreas with the control group (part 1)
Fig. 3
Fig. 3
Comparing artificial pancreas with the control group (part 2)
See this image and copyright information in PMC

References

    1. Zayed H. Genetic epidemiology of type 1 diabetes in the 22 Arab countries. Curr Diab Rep. 2016;16(5):37. doi: 10.1007/s11892-016-0736-4. - DOI - PubMed
    1. Hurren KM, O’Neill JL. Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes. Expert Opin Drug Metab Toxicol. 2016;12(12):1521–1526. doi: 10.1080/17425255.2016.1245722. - DOI - PubMed
    1. McEwan P, Bennett H, Fellows J, Priaulx J, Bergenheim K. The health economic value of changes in glycaemic control, weight and rates of hypoglycaemia in type 1 diabetes mellitus. PLoS One. 2016;11(9):e0162441. doi: 10.1371/journal.pone.0162441. - DOI - PMC - PubMed
    1. Ramirez-Rincon A, Hincapie-García J, Arango CM, et al. Clinical outcomes after 1 year of augmented insulin pump therapy in patients with diabetes in a specialized diabetes center in Medellín, Colombia. Diabetes Technol Ther. 2016;18(11):713–718. doi: 10.1089/dia.2016.0166. - DOI - PubMed
    1. Voelker R. “Artificial pancreas” is approved. JAMA. 2016;316(19):1957. - PubMed